EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseVergleichsstudieOpen Access · CC BY-NC 4.0

Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis

Ye Yuan, Xumei Liu, Gaifeng Xu, Ji Zhang, Li Chen, Xin Long

Cancer Treatment Reviews · 2025-03 · 134 · 102901

DOI: 10.1016/j.ctrv.2025.102901 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Treatment Reviews, 2025-03. Verfasst von Ye Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Integrative Medicine Hospital, China. Electronic address: yuanyeah0811@163.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Aminoquinolines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsAminoquinolinesAcrylamidesHumansFemaleErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

HER2-positive breast cancerMeta-analysisNeoadjuvant treatmentPertuzumabPyrotinibSystematic reviewTrastuzumab

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedAminoquinolinesAcrylamidespertuzumabERBB2 protein, humanpyrotinib

Autor:innen und Institutionen

  • Sichuan Integrative Medicine Hospital, China. Electronic address: yuanyeah0811@163.com.
  • Chengdu Anticancer Bioscience, China.
  • Sichuan Integrative Medicine Hospital, China.
  • Sichuan Integrative Medicine Hospital, China. Electronic address: 26011707@qq.com.

Zitieren

APA

Yuan, Y., Liu, X., Xu, G., Zhang, J., Chen, L., & Long, X. (2025). Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 134, 102901. https://doi.org/10.1016/j.ctrv.2025.102901

Vancouver

Yuan Y, Liu X, Xu G, Zhang J, Chen L, Long X. Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews. 2025;134:102901. doi:10.1016/j.ctrv.2025.102901

BibTeX
@article{Yuan2025,
  author = {Yuan, Ye and Liu, Xumei and Xu, Gaifeng and Zhang, Ji and Chen, Li and Long, Xin},
  title = {Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis},
  journal = {Cancer Treatment Reviews},
  year = {2025},
  volume = {134},
  pages = {102901},
  doi = {10.1016/j.ctrv.2025.102901}
}
Kostenlos starten →